FINANCIAL NEWS FAST

U.S. government begins two trials testing Eli Lilly’s coronavirus antibody drug

The trials, called ACTIV-2 and ACTIV-3, will look at U.S. drugmaker Eli Lilly’s experimental treatment known as LY-CoV555, which is being developed in partnership with Canadian biotech company AbCellera.The trials, called ACTIV-2 and ACTIV-3, will look at U.S. drugmaker Eli Lilly’s experimental treatment known as LY-CoV555, which is being developed in partnership with Canadian biotech company AbCellera.Read More

Share:

Share on facebook
Facebook
Share on twitter
Twitter
Share on pinterest
Pinterest
Share on linkedin
LinkedIn
On Key

Related Posts

Fortune Org is an international news provider focusing on trusted financial, political, and world news for professionals and organizations. Our editor in chief Brian Edwards runs our tight-knit team of investigative journalists and finance researchers from the UK and Australia that contribute to curated news content, op-eds, and investigative pieces.

Financial News Fast

Copyright © 2020 Fortune Org.